SLDB
Solid Biosciences Inc.
Price Chart
Latest Quote
$6.19
+0.38 (+6.54%)
Current Price
| Previous Close | $5.81 |
| Open | $5.84 |
| Day High | $6.22 |
| Day Low | $5.77 |
| Volume | 1,550,430 |
Stock Information
| Shares Outstanding | 107.23M |
| Total Debt | $20.16M |
| Cash Equivalents | $377.68M |
| Net Income | $-207.10M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $663.72M |
| EPS (TTM) | $-1.89 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $306.20M |
| Income | $-207.10M |
| Book/sh | $3.56 |
| Cash/sh | $3.52 |
| Employees | 121 |
Financial Ratios
| Quick Ratio | 13.21 |
| Current Ratio | 13.82 |
| Debt/Eq | 5.39 |
Returns & Margins
| ROA | -36.38% |
| ROE | -65.50% |
Ownership
| Insider Ownership | 0.69% |
| Institutional Ownership | 107.56% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.62 |
| P/B | 1.74 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $18.71 |
Technical Indicators
| SMA20 | $6.38 |
| SMA50 | $7.99 |
| SMA200 | $7.65 |
| RSI | 41.38 |
| ATR | 0.4371 |
| Shares Float | 64.80M |
| Short Float | 13.49% |
| Short Ratio | 10.04 |
| Volatility | 2.47 |
| Rel Volume | 1.10 |
Performance History
| Week | -3.28% |
| Month | -14.97% |
| Quarter | -23.01% |
| 6 Months | -16.91% |
| YTD | +13.58% |
| Year | +10.14% |
| 3 Years | +194.76% |
| 5 Years | -80.98% |
| 10 Years | -98.18% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $6.19 | 1,550,400 |
| 2026-10-26 | $5.81 | 1,070,900 |
| 2026-10-23 | $5.92 | 770,000 |
| 2026-10-22 | $6.19 | 1,216,600 |
| 2026-10-21 | $6.41 | 1,147,200 |
| 2026-10-20 | $6.40 | 1,465,100 |
| 2026-10-19 | $5.92 | 1,847,900 |
| 2026-10-16 | $5.53 | 1,401,800 |
| 2026-10-15 | $5.74 | 2,033,400 |
| 2026-10-14 | $5.47 | 2,378,300 |
| 2026-10-13 | $5.82 | 2,869,600 |
| 2026-10-12 | $6.71 | 601,300 |
| 2026-10-09 | $6.87 | 726,800 |
| 2026-10-08 | $6.82 | 1,308,100 |
| 2026-10-07 | $6.85 | 744,600 |
| 2026-10-06 | $6.92 | 1,188,600 |
| 2026-10-05 | $7.06 | 1,371,700 |
| 2026-10-02 | $6.85 | 1,198,200 |
| 2026-10-01 | $6.98 | 1,581,700 |
| 2026-09-30 | $7.23 | 1,711,200 |
| 2026-09-29 | $7.16 | 1,392,300 |
| 2026-09-28 | $7.28 | 1,413,500 |
About Solid Biosciences Inc.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
đ° Latest News
No news articles available at the moment. Check back later for updates on SLDB.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $8,094,000 |
| Operating Revenue | $0 | $0 | $0 | $8,094,000 |
| Expenses | ||||
| Total Expenses | $179,206,000 | $129,728,000 | $104,315,000 | $107,368,000 |
| Other Income Expense | $-5,226,000 | $-4,098,000 | $1,158,000 | $10,677,000 |
| Other Non Operating Income Expenses | $824,000 | $652,000 | $1,095,000 | $-381,000 |
| Net Non Operating Interest Income Expense | $10,107,000 | $9,129,000 | $7,142,000 | $2,616,000 |
| Operating Expense | $179,206,000 | $129,728,000 | $104,315,000 | $107,368,000 |
| General And Administrative Expense | $38,881,000 | $33,297,000 | $27,752,000 | $28,948,000 |
| Interest Expense | - | $340,000 | $440,000 | - |
| Interest Expense Non Operating | - | $340,000 | $440,000 | - |
| Total Other Finance Cost | - | - | - | $-2,616,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-174,325,000 | $-124,697,000 | $-96,015,000 | $-85,981,000 |
| Net Interest Income | $10,107,000 | $9,129,000 | $7,142,000 | $2,616,000 |
| Interest Income | $10,107,000 | $9,469,000 | $7,582,000 | $2,616,000 |
| Normalized Income | $-168,275,000 | $-119,947,000 | $-96,078,000 | $-97,039,000 |
| Net Income From Continuing And Discontinued Operation | $-174,325,000 | $-124,697,000 | $-96,015,000 | $-85,981,000 |
| Total Operating Income As Reported | $-179,206,000 | $-129,728,000 | $-104,252,000 | $-106,452,000 |
| Net Income Common Stockholders | $-174,325,000 | $-124,697,000 | $-96,015,000 | $-85,981,000 |
| Net Income | $-174,325,000 | $-124,697,000 | $-96,015,000 | $-85,981,000 |
| Net Income Including Noncontrolling Interests | $-174,325,000 | $-124,697,000 | $-96,015,000 | $-85,981,000 |
| Net Income Continuous Operations | $-174,325,000 | $-124,697,000 | $-96,015,000 | $-85,981,000 |
| Pretax Income | $-174,325,000 | $-124,697,000 | $-96,015,000 | $-85,981,000 |
| Interest Income Non Operating | $10,107,000 | $9,469,000 | $7,582,000 | $2,616,000 |
| Operating Income | $-179,206,000 | $-129,728,000 | $-104,315,000 | $-99,274,000 |
| Special Income Charges | - | $0 | $63,000 | $11,058,000 |
| Per Share | ||||
| Diluted EPS | $-1.99 | $-3.06 | $-4.83 | $-10.10 |
| Basic EPS | $-1.99 | $-3.06 | $-4.83 | $-10.10 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-171,520,000 | $-117,152,000 | $-93,057,000 | $-107,924,000 |
| Total Unusual Items | $-6,050,000 | $-4,750,000 | $63,000 | $11,058,000 |
| Total Unusual Items Excluding Goodwill | $-6,050,000 | $-4,750,000 | $63,000 | $11,058,000 |
| Reconciled Depreciation | $1,636,000 | $2,455,000 | $2,581,000 | $2,408,000 |
| EBITDA (Bullshit earnings) | $-177,570,000 | $-121,902,000 | $-92,994,000 | $-96,866,000 |
| EBIT | $-179,206,000 | $-124,357,000 | $-95,575,000 | $-99,274,000 |
| Diluted Average Shares | $87,504,631 | $40,816,694 | $19,884,007 | $8,512,089 |
| Basic Average Shares | $87,504,631 | $40,816,694 | $19,884,007 | $8,512,089 |
| Diluted NI Availto Com Stockholders | $-174,325,000 | $-124,697,000 | $-96,015,000 | $-85,981,000 |
| Gain On Sale Of Security | $-6,050,000 | $-4,750,000 | - | - |
| Research And Development | $140,325,000 | $96,431,000 | $76,563,000 | $78,420,000 |
| Selling General And Administration | $38,881,000 | $33,297,000 | $27,752,000 | $28,948,000 |
| Other Gand A | $38,881,000 | $33,297,000 | $27,752,000 | $28,948,000 |
| Restructuring And Mergern Acquisition | - | $0 | $-63,000 | $-11,058,000 |
Fetched: 2026-10-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $180,010,000 | $137,246,000 | $126,481,000 | $211,666,000 |
| Total Assets | $232,540,000 | $188,662,000 | $164,939,000 | $260,252,000 |
| Total Non Current Assets | $27,084,000 | $31,360,000 | $35,205,000 | $40,614,000 |
| Other Non Current Assets | $991,000 | $2,318,000 | $2,042,000 | $2,008,000 |
| Current Assets | $205,456,000 | $157,302,000 | $129,734,000 | $219,638,000 |
| Other Current Assets | $2,415,000 | $1,651,000 | $2,114,000 | $3,003,000 |
| Restricted Cash | $1,222,000 | $0 | - | - |
| Prepaid Assets | $13,969,000 | $6,731,000 | $3,980,000 | $2,913,000 |
| Cash Cash Equivalents And Short Term Investments | $187,850,000 | $148,920,000 | $123,640,000 | $213,722,000 |
| Cash And Cash Equivalents | $59,900,000 | $80,235,000 | $74,015,000 | $155,384,000 |
| Receivables | - | - | - | $0 |
| Accounts Receivable | - | - | - | $0 |
| Debt | ||||
| Total Debt | $21,161,000 | $24,177,000 | $26,265,000 | $28,547,000 |
| Long Term Debt And Capital Lease Obligation | $19,058,000 | $21,159,000 | $23,941,000 | $25,982,000 |
| Current Debt And Capital Lease Obligation | $2,103,000 | $3,018,000 | $2,324,000 | $2,565,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $52,530,000 | $51,416,000 | $38,458,000 | $48,586,000 |
| Total Non Current Liabilities Net Minority Interest | $19,058,000 | $21,159,000 | $23,941,000 | $26,078,000 |
| Current Liabilities | $33,472,000 | $30,257,000 | $14,517,000 | $22,508,000 |
| Other Current Liabilities | $9,200,000 | $3,150,000 | $24,000 | $14,000 |
| Payables And Accrued Expenses | $13,354,000 | $17,868,000 | $6,245,000 | $11,559,000 |
| Payables | $3,224,000 | $4,237,000 | $2,032,000 | $3,238,000 |
| Accounts Payable | $3,224,000 | $4,237,000 | $2,032,000 | $3,238,000 |
| Other Non Current Liabilities | - | - | - | $96,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $180,010,000 | $137,246,000 | $126,481,000 | $211,666,000 |
| Total Equity Gross Minority Interest | $180,010,000 | $137,246,000 | $126,481,000 | $211,666,000 |
| Stockholders Equity | $180,010,000 | $137,246,000 | $126,481,000 | $211,666,000 |
| Gains Losses Not Affecting Retained Earnings | $52,000 | $47,000 | $15,000 | $-68,000 |
| Other Equity Adjustments | $52,000 | $47,000 | $15,000 | $-68,000 |
| Retained Earnings | $-957,775,000 | $-783,450,000 | $-658,753,000 | $-562,738,000 |
| Other | ||||
| Ordinary Shares Number | $78,967,888 | $40,468,141 | $20,386,606 | $19,556,732 |
| Share Issued | $78,967,888 | $40,468,141 | $20,386,606 | $19,556,732 |
| Tangible Book Value | $180,010,000 | $137,246,000 | $126,481,000 | $211,666,000 |
| Invested Capital | $180,010,000 | $137,246,000 | $126,481,000 | $211,666,000 |
| Working Capital | $171,984,000 | $127,045,000 | $115,217,000 | $197,130,000 |
| Capital Lease Obligations | $21,161,000 | $24,177,000 | $26,265,000 | $28,547,000 |
| Total Capitalization | $180,010,000 | $137,246,000 | $126,481,000 | $211,666,000 |
| Additional Paid In Capital | $1,137,654,000 | $920,609,000 | $785,199,000 | $774,452,000 |
| Capital Stock | $79,000 | $40,000 | $20,000 | $20,000 |
| Common Stock | $79,000 | $40,000 | $20,000 | $20,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $19,058,000 | $21,159,000 | $23,941,000 | $25,982,000 |
| Current Capital Lease Obligation | $2,103,000 | $3,018,000 | $2,324,000 | $2,565,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $8,815,000 | $6,221,000 | $5,948,000 | $8,370,000 |
| Current Accrued Expenses | $10,130,000 | $13,631,000 | $4,213,000 | $8,321,000 |
| Net PPE | $26,093,000 | $29,042,000 | $33,163,000 | $38,606,000 |
| Accumulated Depreciation | $-14,190,000 | $-13,026,000 | $-12,735,000 | $-10,956,000 |
| Gross PPE | $40,283,000 | $42,068,000 | $45,898,000 | $49,562,000 |
| Leases | $483,000 | $470,000 | $481,000 | $384,000 |
| Construction In Progress | $397,000 | $879,000 | $410,000 | $1,715,000 |
| Other Properties | $37,550,000 | $38,699,000 | $42,676,000 | $45,365,000 |
| Machinery Furniture Equipment | $1,853,000 | $2,020,000 | $2,331,000 | $2,098,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $127,950,000 | $68,685,000 | $49,625,000 | $58,338,000 |
| Treasury Shares Number | - | - | $0 | - |
| Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-10-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-157,442,000 | $-100,666,000 | $-95,695,000 | $-100,992,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-156,289,000 | $-100,012,000 | $-94,180,000 | $-97,977,000 |
| Cash Flow From Continuing Operating Activities | $-156,289,000 | $-100,012,000 | $-94,180,000 | $-97,977,000 |
| Operating Gains Losses | $6,050,000 | $4,750,000 | $374,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,153,000 | $-654,000 | $-1,515,000 | $-3,015,000 |
| Investing Cash Flow | $-58,454,000 | $-16,086,000 | $9,689,000 | $59,157,000 |
| Cash Flow From Continuing Investing Activities | $-58,454,000 | $-16,086,000 | $9,689,000 | $59,157,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,681,000 | $-5,111,000 | $0 | - |
| Issuance Of Capital Stock | $196,419,000 | $127,227,000 | $2,974,000 | $72,551,000 |
| Financing Cash Flow | $194,446,000 | $122,437,000 | $3,122,000 | $74,831,000 |
| Cash Flow From Continuing Financing Activities | $194,446,000 | $122,437,000 | $3,122,000 | $74,831,000 |
| Net Common Stock Issuance | $194,738,000 | $122,116,000 | $2,974,000 | $72,551,000 |
| Common Stock Issuance | $196,419,000 | $127,227,000 | $2,974,000 | $72,551,000 |
| Other | ||||
| Repayment Of Debt | $-723,000 | $-473,000 | $0 | $-66,000 |
| End Cash Position | $61,890,000 | $82,187,000 | $75,848,000 | $157,217,000 |
| Beginning Cash Position | $82,187,000 | $75,848,000 | $157,217,000 | $121,206,000 |
| Changes In Cash | $-20,297,000 | $6,339,000 | $-81,369,000 | $36,011,000 |
| Proceeds From Stock Option Exercised | $431,000 | $794,000 | $148,000 | $203,000 |
| Common Stock Payments | $-1,681,000 | $-5,111,000 | $0 | - |
| Net Issuance Payments Of Debt | $-723,000 | $-473,000 | $0 | $2,077,000 |
| Net Long Term Debt Issuance | $-723,000 | $-473,000 | $0 | $2,077,000 |
| Long Term Debt Payments | $-723,000 | $-473,000 | $0 | $-66,000 |
| Net Investment Purchase And Sale | $-57,386,000 | $-15,437,000 | $11,204,000 | $30,049,000 |
| Sale Of Investment | $178,500,000 | $188,900,000 | $128,632,000 | $212,811,000 |
| Purchase Of Investment | $-235,886,000 | $-204,337,000 | $-117,428,000 | $-182,762,000 |
| Net PPE Purchase And Sale | $-1,068,000 | $-649,000 | $-1,515,000 | $-2,415,000 |
| Sale Of PPE | $85,000 | $5,000 | $0 | $600,000 |
| Purchase Of PPE | $-1,153,000 | $-654,000 | $-1,515,000 | $-3,015,000 |
| Change In Working Capital | $-6,822,000 | $2,850,000 | $-8,868,000 | $-3,689,000 |
| Change In Other Current Liabilities | $-1,786,000 | $-1,676,000 | $-1,735,000 | - |
| Change In Payables And Accrued Expense | $2,957,000 | $6,971,000 | $-7,731,000 | $586,000 |
| Change In Accrued Expense | $4,050,000 | $4,766,000 | $-6,967,000 | $5,832,000 |
| Change In Payable | $-1,093,000 | $2,205,000 | $-764,000 | $-5,246,000 |
| Change In Account Payable | $-1,093,000 | $2,205,000 | $-764,000 | $-5,246,000 |
| Change In Prepaid Assets | $-7,993,000 | $-2,445,000 | $598,000 | $3,695,000 |
| Other Non Cash Items | $2,132,000 | $7,703,000 | $2,905,000 | $-18,485,000 |
| Stock Based Compensation | $16,914,000 | $10,519,000 | $7,625,000 | $7,537,000 |
| Amortization Of Securities | $-1,874,000 | $-3,592,000 | $-2,408,000 | $233,000 |
| Depreciation Amortization Depletion | $1,636,000 | $2,455,000 | $2,581,000 | $2,408,000 |
| Depreciation And Amortization | $1,636,000 | $2,455,000 | $2,581,000 | $2,408,000 |
| Depreciation | $1,636,000 | $2,455,000 | $2,581,000 | $2,408,000 |
| Gain Loss On Investment Securities | $6,050,000 | $4,750,000 | - | - |
| Net Income From Continuing Operations | $-174,325,000 | $-124,697,000 | $-96,015,000 | $-85,981,000 |
| Issuance Of Debt | - | - | $0 | $2,143,000 |
| Long Term Debt Issuance | - | - | $0 | $2,143,000 |
| Net Business Purchase And Sale | - | - | $0 | $31,523,000 |
| Sale Of Business | - | - | $0 | $31,523,000 |
| Change In Receivables | - | - | $0 | $110,000 |
| Changes In Account Receivables | - | - | $0 | $110,000 |
| Gain Loss On Sale Of PPE | - | - | $374,000 | $0 |
| Change In Other Working Capital | - | - | - | $-8,080,000 |
Fetched: 2026-10-25